Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ImmVira Approved to Start Trials of IV Oncolytic Virus Therapy

publication date: Aug 6, 2021

Shenzhen ImmVira was approved start a Phase I trial of its lead intravenous oncolytic virus therapy in China. The company says the product is the first IV oncolytic virus in the world to start clinical trials. MVR-T3011 is a novel genetic engineered oHSV (herpes virus) that uses attenuated HSV-1, which is designed for best replication potency and safety. It is a 3-in-1 oHSV containing both a PD1 mAb and IL12. ImmVira says the candidate is a novel next-gen design based on ImmVira's oncolytic viruses insights and gene recombinant technology. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital